<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Profiling of Syngeneic Models by Check Point Inhibitors, RNAseq, and FACS Analysis Enables Better Selection of Models for Immune Targeted Combination Therapy

Syngeneic tumor models have long been used in cancer research. The recent clinical success of anti-CTLA-4 and anti-PD1 antibodies contributed to increasing the interest around syngeneic models to evaluate cancer immunotherapy.